Evidence map›Paper›PMID 20639760›Full record

ReviewCurrent opinion in oncology2010

Hematopoietic stem cell transplantation for AIDS-related malignancies.

Amrita Krishnan, Stephen J Forman

Abstract readReview
In one paragraph

Review in Current opinion in oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Hematopoietic cell transplantation with cord blood for cure of HIV infections.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2013
    Article
  5. HIV-1 and hematopoietic stem cell transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amrita KrishnanDivision of Hematology/Hematopoietic Stem Cell Transplant, City of Hope Cancer Center, Duarte, California, USA. akrishnan@coh.org
Stephen J Forman
City of Hope · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
Transplant for Lymphoma:Therapy-Related LeukemiaP50CA107399 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI FORMAN, STEPHEN J, KWAK, LARRY W · 2004 to 2022
$35.5M
Vaccine-Induced Immunity to CMVP01CA030206 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI FORMAN, STEPHEN J · 1985 to 2010
$31.8M
NCI NIH HHS P01 CA030206NCI NIH HHS P30 CA033572NCI NIH HHS P50 CA107399
6 · The paper itself

Abstract

purpose of reviewAIDS-related malignancies are an ongoing cause of mortality in individuals with HIV infection. In the HIV-negative setting, high-dose chemotherapy or stem cell transplantation is an option for patients with hematologic malignancies. Prior to the advent of effective HIV therapy, stem cell transplantation was not feasible for HIV-positive patients. The purpose of this article is to explore the transplant options for HIV-positive patients after widespread use of highly active antiretroviral therapy. RECENT

findingsEarly autologous stem cell transplantation has studies had high relapse rates but they demonstrated that mobilization and engraftment of autologous stem cells were possible in AIDS patients. Recently, in less advanced AIDS lymphoma, autologous stem cell transplantation has resulted in low transplant-related mortality and durable remissions. In addition, case-control studies of HIV-positive versus HIV-negative lymphoma patients undergoing autologous stem cell transplantation have shown similar transplant-related mortality and overall survival. The feasibility of allogeneic stem cell transplantation in HIV-infected individuals is less tested. There are challenges of drug interactions between highly active antiretroviral therapy and immunosuppressive agents as well as the potential for higher infection rates. SUMMARY: The potential future applications of autologous and allogeneic stem cell transplantation are the cure of the malignancy as well as the underlying HIV infection by either transplantation of naturally resistant or genetically modified stem cells.

Indexed as

Hematopoietic Stem Cell TransplantationHumansLymphoma, AIDS-RelatedTreatment Outcome

Identifiers

PMID20639760
PMCPMC3537514
OpenAlexW1977177626

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.